Literature DB >> 25640886

Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells.

A Pardanani1, T Lasho1, D Chen2, T K Kimlinger1, C Finke1, D Zblewski1, M M Patnaik1, K K Reichard2, E Rowinsky3, C A Hanson2, C Brooks3, A Tefferi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25640886     DOI： 10.1038/leu.2015.16

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  11 in total

1.  Failure to detect IL-3-binding sites on human mast cells.

Authors:  P Valent; J Besemer; C Sillaber; J H Butterfield; R Eher; O Majdic; K Kishi; W Klepetko; F Eckersberger; K Lechner
Journal:  J Immunol       Date:  1990-11-15       Impact factor: 5.422

2.  The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells.

Authors:  C T Jordan; D Upchurch; S J Szilvassy; M L Guzman; D S Howard; A L Pettigrew; T Meyerrose; R Rossi; B Grimes; D A Rizzieri; S M Luger; G L Phillips
Journal:  Leukemia       Date:  2000-10       Impact factor: 11.528

3.  Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

Authors:  Stefan Florian; Karoline Sonneck; Alexander W Hauswirth; Maria-Theresa Krauth; Gerit-Holger Schernthaner; Wolfgang R Sperr; Peter Valent
Journal:  Leuk Lymphoma       Date:  2006-02

4.  Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Authors:  Arthur E Frankel; Jung H Woo; Chul Ahn; Naveen Pemmaraju; Bruno C Medeiros; Hetty E Carraway; Olga Frankfurt; Stephen J Forman; Xuezhong A Yang; Marina Konopleva; Francine Garnache-Ottou; Fanny Angelot-Delettre; Christopher Brooks; Michael Szarek; Eric Rowinsky
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

5.  Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

Authors:  Cristina Teodosio; Andrés C García-Montero; María Jara-Acevedo; Laura Sánchez-Muñoz; Ivan Alvarez-Twose; Rosa Núñez; Lawrence B Schwartz; Andrew F Walls; Luis Escribano; Alberto Orfao
Journal:  J Allergy Clin Immunol       Date:  2010-01-12       Impact factor: 10.793

6.  Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice.

Authors:  D Metcalf; C G Begley; G R Johnson; N A Nicola; A F Lopez; D J Williamson
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

7.  A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands.

Authors:  J M Woodcock; C J Bagley; B Zacharakis; A F Lopez
Journal:  J Biol Chem       Date:  1996-10-18       Impact factor: 5.157

8.  A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

Authors:  Simon Z He; Samantha Busfield; David S Ritchie; Mark S Hertzberg; Simon Durrant; Ian D Lewis; Paula Marlton; Andrew J McLachlan; Ian Kerridge; Kenneth F Bradstock; Glen Kennedy; Andrew W Boyd; Trina M Yeadon; Angel F Lopez; Hayley S Ramshaw; Harry Iland; Simone Bamford; Megan Barnden; Mark DeWitte; Russell Basser; Andrew W Roberts
Journal:  Leuk Lymphoma       Date:  2014-11-20

9.  SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia.

Authors:  Olga Frolova; Juliana Benito; Chris Brooks; Rui-Yu Wang; Borys Korchin; Eric K Rowinsky; Jorge Cortes; Hagop Kantarjian; Michael Andreeff; Arthur E Frankel; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-06-19       Impact factor: 6.998

10.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10
View more
  15 in total

1.  CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value.

Authors:  A Pardanani; K K Reichard; D Zblewski; R A Abdelrahman; E A Wassie; W G Morice Ii; C Brooks; K L Grogg; C A Hanson; A Tefferi; D Chen
Journal:  Leukemia       Date:  2015-12-18       Impact factor: 11.528

Review 2.  Role of the β Common (βc) Family of Cytokines in Health and Disease.

Authors:  Timothy R Hercus; Winnie L T Kan; Sophie E Broughton; Denis Tvorogov; Hayley S Ramshaw; Jarrod J Sandow; Tracy L Nero; Urmi Dhagat; Emma J Thompson; Karen S Cheung Tung Shing; Duncan R McKenzie; Nicholas J Wilson; Catherine M Owczarek; Gino Vairo; Andrew D Nash; Vinay Tergaonkar; Timothy Hughes; Paul G Ekert; Michael S Samuel; Claudine S Bonder; Michele A Grimbaldeston; Michael W Parker; Angel F Lopez
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

3.  Detection of circulating mast cells in advanced systemic mastocytosis.

Authors:  J S Dahlin; J S Ungerstedt; J Grootens; B Sander; T Gülen; H Hägglund; G Nilsson
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

Review 4.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

5.  KIT signaling is dispensable for human mast cell progenitor development.

Authors:  Joakim S Dahlin; Maria Ekoff; Jennine Grootens; Liza Löf; Rose-Marie Amini; Hans Hagberg; Johanna S Ungerstedt; Ulla Olsson-Strömberg; Gunnar Nilsson
Journal:  Blood       Date:  2017-08-08       Impact factor: 22.113

6.  Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of thirty-nine patients.

Authors:  Prateek Pophali; Pedro Horna; Terra L Lasho; Christy M Finke; Rhett P Ketterling; Naseema Gangat; David Nagorney; Ayalew Tefferi; Mrinal M Patnaik
Journal:  Am J Hematol       Date:  2018-10-05       Impact factor: 10.047

7.  Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.

Authors:  Pinar Ataca Atilla; Mary K McKenna; Norihiro Watanabe; Maksim Mamonkin; Malcolm K Brenner; Erden Atilla
Journal:  Cytotherapy       Date:  2021-12-23       Impact factor: 5.414

Review 8.  Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.

Authors:  Vincenzo Nasillo; Giovanni Riva; Ambra Paolini; Fabio Forghieri; Luca Roncati; Beatrice Lusenti; Monica Maccaferri; Andrea Messerotti; Valeria Pioli; Andrea Gilioli; Francesca Bettelli; Davide Giusti; Patrizia Barozzi; Ivana Lagreca; Rossana Maffei; Roberto Marasca; Leonardo Potenza; Patrizia Comoli; Rossella Manfredini; Antonino Maiorana; Enrico Tagliafico; Mario Luppi; Tommaso Trenti
Journal:  Int J Mol Sci       Date:  2021-02-14       Impact factor: 5.923

Review 9.  Targeted Treatment Options in Mastocytosis.

Authors:  Mélanie Vaes; Fleur Samantha Benghiat; Olivier Hermine
Journal:  Front Med (Lausanne)       Date:  2017-07-20

Review 10.  New Insights into the Pathogenesis of Systemic Mastocytosis.

Authors:  Zhixiong Li
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.